Search Results - "Czejka, M"

Evaluation of real‐time data obtained from gravimetric preparation of antineoplastic agents shows medication errors with possible critical therapeutic impact: Results of a large‐scale, multicentre, multinational, retrospective study by Terkola, R., Czejka, M., Bérubé, J.

“…Summary What is known and objective Medication errors are a significant cause of morbidity and mortality especially with antineoplastic drugs, owing to their…”
Get full text

Multiple dose pharmacokinetics of erlotinib when combined with gastric acid reducing agents: A comparison with a physiologically based pharmacokinetic model by Hrgovcic, A. Sahmanovic, Gruber, A., Dittrich, C., Kitzmueller, M., Buchner, P., Baroian, N. Kirchbaumer, Czejka, M.

Get full text

P-139Monitoring of erlotinib plasma concentrations after long time administration of 100 mg in advanced pancreatic cancer patients by Sahmanovic, A, Buchner, P, Lichtneckert, M, Dittrich, C, Farkouh, A, Gruber, A, Baroian, N, Kitzmueller, M, Czejka, M

Get full text

2098 Assessment of pharmacokinetic (PK) interaction between cetuximab (CTX) and capecitabine (CCB) or oxaliplatin (OX) in metastatic colorectal cancer (mCRC) patients (pts) (AGMT_CAPECET_PK) by Schreiber, V, Kitzmueller, M, Buchner, P, Weissenboeck, N, Lichtneckert, M, Greil, R, Geiler, H, Czejka, M, Dittrich, C

Get full text

Metabolic Activation of Irinotecan during Intra-arterial Chemotherapy of Metastatic Colorectal Cancer by CZEJKA, M, KISS, A, KOESSNER, C, TERKOLA, R, ETTLINGER, D, SCHUELLER, J

“…Biotransformation of irinotecan (CPT-11) into its pharmacologic active metabolite SN-38 was investigated in patients treated for advanced colorectal cancer. A…”
Get full text

Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels by Czejka, M., Sahmanovic, A., Buchner, P., Steininger, T., Dittrich, C.

“…Erlotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for the treatment of non-small cell lung cancer and when…”
Get full text

Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) with two different capecitabine/oxaliplatin dosage regimens by Farkouh, A, Schueller, J, Scheithauer, W, Czejka, M

Get full text

Evidence for the conversion of docetaxel into 7'-epidocetaxel in patients receiving Taxotere-based conventional chemotherapy by Czejka, M, Greil, R, Ulsperger, E, Schnait, H, Kienesberger, K, Brumnik, T, Farkouh, A, Schierholz, J

Get full text

Systemic side effects of eye drops: a pharmacokinetic perspective by Farkouh, Andre, Frigo, Peter, Czejka, Martin

“…When administering eye drops, even when completely correctly applied, several routes of absorption are possible and excess amounts can sometimes cause an…”
Get full text

6090 Influence of Cetuximab applied as biweekly infusion on the plasma disposition of CPT 11 and its metabolites in advanced colorectal cancer by Schueller, J, Czejka, M, Kiss, A, Farkouh, A, Aigner, K, Krexner, E, Gruenberger, B

Get full text

Disposition of paclitaxel (Taxol®) and its metabolites in patients with advanced breast cancer (ABC) when combined with trastuzumab (Hercpetin®) by FURTLEHNER, A, SCHUELLER, J, JARISCH, I, OSTERMANN, E, CZEJKA, M

“…Monoclonal antibodies are capable of modulating drug metabolising enzymes resulting in unexpected plasma concentrations of a drug when given concomitantly…”
Get full text

P-168Multiple dose pharmacokinetics of erlotinib when combined with gastric acid reducing agents: A comparison with a physiologically based pharmacokinetic model by Hrgovcic, A Sahmanovic, Gruber, A, Dittrich, C, Kitzmueller, M, Buchner, P, Baroian, N Kirchbaumer, Czejka, M

Get full text

Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP) by LINKESCH, W, WEGER, M, EDER, I, AUNER, H. W, PERNEGG, C, KRAULE, C, CZEJKA, M. J

“…The concentration-time profiles of Doxorubicin (DOXO) from day 0 to day 21 after i.v. infusion of 25 or 30 mg/m2 doxorubicin HCI stealth liposomes (Caelyx)…”
Get full text

Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil by SCHEITHAUER, W, SCHENK, T, CZEJKA, M

“…The potential for a pharmacokinetic interaction between epirubicin and the second-generation multidrug resistance modulating agent D-verapamil (DVPM) has been…”
Get full text

P-139 Monitoring of erlotinib plasma concentrations after long time administration of 100 mg in advanced pancreatic cancer patients by Sahmanovic, A., Buchner, P., Lichtneckert, M., Dittrich, C., Farkouh, A., Gruber, A., Baroian, N., Kitzmueller, M., Czejka, M.

Get full text

Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine by Czejka, M, Schueller, J, Eder, I, Reznicek, G, Kraule, C, Zeleni, U, Freitag, R

“…Cytoprotection of healthy cells represents a new approach in cancer chemotherapy, but a pharmacokinetic drug interaction between the cytostatic and the…”
Get more information

701PPHASE IB TRIAL TO EVALUATE CAPECITABINE (C), ERLOTINIB (E), AND BEVACIZUMAB (B) IN PATIENTS (PTS) WITH UNRESECTABLE AND/OR METASTATIC PANCREATIC CANCER (UMPC) – PRELIMINARY RESULTS OF THE REBECA TRIAL INCLUDING PHARMACOKINETICS (PK) AND CIRCULATING TUMOR CELLS (CTCS) by Dittrich, C., Buchner, P., Sahmanovic, A., Königsberg, R., Lichtneckert, M., Nirnberger, G., Czejka, M., Geissler, K.

“…Abstract Aim: UMPC represents an unmet therapeutic need. Maximum tolerated dose (MTD), PK, safety, and doses recommended for phase II (RPIID) of CEB were…”
Get full text

Phase Ib Trial to Evaluate Capecitabine (C), Erlotinib (E), and Bevacizumab (B) in Patients (Pts) with Unresectable and/or Metastatic Pancreatic Cancer (Umpc) – Preliminary Results of the Rebeca Trial Including Pharmacokinetics (Pk) and Circulating Tumor Cells (Ctcs) by Dittrich, C., Buchner, P., Sahmanovic, A., Königsberg, R., Lichtneckert, M., Nirnberger, G., Czejka, M., Geissler, K.

Get full text

Influence of interferon alfa-2b with or without folinic acid on pharmacokinetics of fluorouracil by Schüller, J, Czejka, M J, Schernthaner, G, Fogl, U, Jäger, W, Micksche, M

“…Interferon alfa has been demonstrated to enhance the effect of fluorouracil (5-FU) on human colon cancer cell lines as well as in clinical studies. By several…”
Get more information

Disposition of 5-formyl- and 5-methyltetrahydrofolic acid in serum after i.v. bolus of calcium folinate : pharmacokinetic drug interaction with preadministered interferon-alpha-2b by CZEJKA, M. J, SCHÜLLER, J, WEISS, C, BANDAK, S, MEYER, B, SIMON, D

“…The influence of interferon (IFN) coadministered subcutaneously with the biomodulating agent folinic acid on the blood serum levels of 5-formyl-tetrahydrofolic…”
Get full text